Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study
| Autor: | Athyros, V. G., Elisaf, M. S., Papageorgiou, A. A., Symeonidis, A. N., Pehlivanidis, A. N., Bouloukos, V. I., Milionis, H. J., Mikhailidis, D. P. |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2004 |
| Předmět: |
Male
Hyperlipidemias/*blood/*drug therapy Creatinine/metabolism Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology/*therapeutic use Lipids/blood Pyrroles/pharmacology/*therapeutic use Coronary Disease/*blood/*drug therapy Heptanoic Acids/pharmacology/*therapeutic use Middle Aged Humans Female Uric Acid/*blood Aged Proportional Hazards Models |
| Popis: | BACKGROUND: Little is known about the effect of dyslipidemia on serum uric acid (SUA) levels, and less is known about the effect of statin treatment on them. The GREek Atorvastatin and Coronary-heart-disease Evaluation study suggested that a mean atorvastatin dose of 24 mg/d achieves the National Cholesterol Educational Program treatment goals and significantly reduces morbidity and mortality in patients with coronary heart disease (CHD) in comparison to the usual care. Here, we report the time course of SUA levels in usual-care patients undertreated for their dyslipidemia (12% were administered statins) in comparison to structured-care patients treated with atorvastatin in the vast majority (98%). METHODS: Mean on-study SUA levels (up to 48 months) were compared with those at baseline by using analyses of variance to assess differences over time within and between treatment groups. Cox multivariate analysis was used to investigate whether changes in SUA levels during the study were clinically relevant. RESULTS: All patients had normal renal function at baseline; serum creatinine (SCr) levels less than 1.3 mg/dL ( |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|